Migraine Pain Management

Part I: Foundations and historical development of migraine pain management<br>1. Introduction<br>2. Neuroanatomy and Neurophysiology<br>3. Historical overview of migraine product development<br>4. Comorbidities and their impact on therapies<br>5. Not all Migraine attacks are the same<br>6. Challenges and Controversies; Pharmacokinetics, Linguistics, Semantics and Statistics<br><br>Part II: Druggable targets<br>7. CGRP<br>8. PACAP<br>9. Src family kinases (SFK) in Migraine<br>10. Delta opioid receptor system<br>11. Piezo channels in peripheral trigeminal nociception<br>12. TRP antagonists<br><br>Part III: Drugs – Acute Management<br>13. Simple analgesics and combination oral products<br>14. Cannabinoids & Phytochemicals<br>15. Ergots<br>16. Triptans<br>17. Beta blocker (timolol) eye drops<br>18. Lasmiditan (and the ditan class)<br>19. Gepants<br><br>Part IV: Drugs – Prevention<br>20. TCAs (Tricyclic Antidepresants), SNRIs, Beta blockers, candesartan, flunarizine<br>21. Antiseizure orals (gabapentin, topiramate)<br>22. Onabotulinumtoxin<br>23. Gepants (for prevention)<br>24. (CGRP) Monocloncal antibodies<br><br>Part V: Administration routes<br>25. Oral Drugs (including SMEDDS)<br>26. Inhaled - oral & nasal<br>27. Subcutaneous/IM/Transcutaneous ("Injectables")<br>28. IV/Infusion<br><br>Part VI: Alternative Management<br>29. The role of digital platforms and smartphone apps<br>30. Herbal Medicines<br>31. Phototherapy<br>32. Neuromodulation<br>33. Acupuncture (for episodic and chronic migraine)<br>34. Manual Therapies<br>35. Nutraceuticals and Diets<br>36. Mindfulness<br><br>Part VII: Summary & conclusion [Shrewsbury]<br>37. Final Perspectives: oral/non-oral pharmaceuticals; devices; Complimentary practices